TORNTPHARM

Torrent Pharmaceuticals – Leading Branded Pharma Franchise with Strong Growth Visibility

Torrent Pharmaceuticals is one of India's leading branded pharmaceutical companies with a strong presence across chronic therapies such as cardiology, diabetology, CNS, and gastroenterology. The company continues to outperform the domestic market through strong brand equity, a large prescription franchise, and growing international operations. A key growth catalyst is the acquisition and integration of JB Chemicals, which strengthens Torrent's market position, expands its product portfolio, and creates long-term synergy opportunities. The company also benefits from a healthy product pipeline, strong cash generation, and consistent margin performance. Key Financial Highlights • FY26 Revenue grew 21% YoY to ₹13,980 crore. • FY26 EBITDA increased 23% YoY to ₹4,559 crore. • EBITDA Margin remained strong at approximately 33%. • FY26 Net Profit rose 12% YoY to ₹2,138 crore. • Strong branded business growth across India and international markets. • Recommended final dividend of ₹9 per share for FY26. Investment Rationale • Leadership in high-growth chronic therapies. • Strong domestic franchise with 20+ leading brands. • JB Chemicals acquisition enhances scale and earnings potential. • Consistent 30%+ EBITDA margins and strong cash flows. • Well-positioned to benefit from rising healthcare spending and pharma demand. Torrent Pharma combines strong brand strength, healthy profitability, strategic acquisitions, and consistent execution, making it a compelling long-term pharmaceutical growth story.